A non-invasive genetic urine test called the GALEAS Bladder urine test correctly identified bladder cancer in 71 of 77 patients in a UK observational study, returning a negative predictive value of greater than 99% and detecting every muscle-invasive case in the cohort. The results, published in European Urology Oncology, add weight to the case for replacing or supplementing the current gold-standard procedure with a test that requires nothing more from a patient than a urine sample.
The study enrolled 964 patients referred for urgent hematuria screening as part of a suspected cancer pathway. According to ScienceDirect, those participants were enrolled between October 2024 and June 2025, and all underwent both standard diagnostic procedures and the GALEAS test so that results could be compared directly. Every participant provided a urine sample; none required a separate clinical appointment specifically for the new test.
What the GALEAS Bladder Urine Test Actually Measures
GALEAS Bladder, developed by Nonacus Clinical Services, is a DNA-based diagnostic that measures mutations across 23 bladder cancer-associated genes. The test subjects a urine sample to a multimarker genetic assay of proteins and other traces of those genes. Because it works on urine collected for any reason, it carries an additional possibility: revealing early signs of bladder cancer in individuals not previously considered at risk.
Out of 77 cases of bladder cancer confirmed through cystoscopy during the study, GALEAS detected 71. The University of Birmingham reports that the test identified all 17 muscle-invasive bladder cancers, a detection rate of 100%, and caught 35 of 36 high-grade cancers, equivalent to 97.2%. Those figures matter clinically: muscle-invasive and high-grade tumours carry the worst prognoses, and catching them early is where any triage tool earns its value.
The test produced 61 false positives and 6 false negatives. Of those 6 missed cases, 4 involved tumours at a very early stage, which the study authors acknowledged as a limitation. Early-stage cancers produce fewer genetic signals in urine, and the test’s current sensitivity at that end of the spectrum remains a challenge the technology has not yet resolved.
The Case Against Cystoscopy Alone
The backdrop to this study is a persistent mismatch between symptoms and confirmed diagnoses. Blood in the urine, known medically as hematuria, is present in more than 90% of patients eventually diagnosed with bladder cancer. Yet only 8 to 19% of hematuria referrals ever produce a positive result. That gap exists partly because the current gold-standard pathway, combining flexible cystoscopy, urinary tract imaging, and analysis of resected tissue, is expensive, invasive, and demands both patient attendance and availability of a urologist and a clinical facility.
Bladder cancer is one of the 10 most common malignancies globally, with around 550,000 cases diagnosed worldwide every year. The CDC estimates that some 84,000 people in the United States will develop it this year alone. Reducing diagnostic delays matters at scale.
Andy Goffe, a Lead Urology Nurse Consultant at Dorset County Hospital Foundation Trust who leads the GALEAS Bladder service evaluation, described the patient experience in blunt terms. ‘The most important message for the patient is that they don’t have to do anything to be part of this,’ he said. ‘We also explain that we’re looking for ways to replace a cystoscopy, so perhaps it is not a surprise that, to date, 100% of patients have agreed to get involved.’
That level of uptake removes one practical obstacle that can quietly undermine trials of new diagnostic tools. A test that patients find burdensome tends to see lower participation, skewed samples, and results that are harder to generalise. A urine sample collected in an existing appointment sidesteps all of that.
The study authors were careful not to overstate what the results mean for clinical practice. Writing as a triage device, they described the test as demonstrating ‘considerable reliability, efficacy, and accuracy’, and noted that deployment at scale ‘could lead to a considerable reduction in the number of urgent cystoscopies undertaken in this setting, thereby reducing waiting times.’ The conditional phrasing is deliberate: the GALEAS Bladder urine test has not yet replaced cystoscopy in any health system, and the path from an observational study to routine commissioning involves regulatory review, cost analysis, and integration into existing referral pathways. The study’s publication in European Urology Oncology puts that process formally in motion.
